CoChat

EVALUATION OF DRUG TREATMENT IN MILD HYPERTENSION: VA‐NHLBI FEASIBILITY TRIAL*: Plan and Preliminary Results of a Two‐Year Feasibility Trial for a Multicenter Intervention Study to Evaluate the Benefits versus the Disadvantages of Treating Mild Hypertension: Prepared for the Veterans Administration‐National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension†

Neurath, H. Mitchell, Goldman, Anne I., Lavin, Mary Ann, Schnaper, Harold W., Fitz, Annette E., Frohlich, Edward D., Steele, Bernard, Richman, Harold G. · 1978 · Annals of the New York Academy of Sciences
Cited by 91

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

A feasibility trial to investigate the practicality of determining the advantages and disadvantages of prompt pharmacologic treatment for mild hypertension was jointly funded by the Veterans Administration and the National Heart, Lung and Blood Institute. Its clinical phase has been completed, and it demonstrated 1. that the required relatively young asymptomatic population could be enrolled in the study and 2. that it could be persuaded to adhere to the protocol for 2 years; however, it was evident that intensive efforts would be required in both areas. The feasibility trial screened almost 120,000 potential subjects over a period of 16 months to randomize about 1,000 subjects at four clinical centers. These men and women were 21 to 50 years old, had diastolic pressures from 85 to 105 mm Hg as outpatients, and had no evidence of cardiovascular renal abnormalities. They were randomized in double-blind fashion into active drug therapy and placebo groups. Stepped care therapy involved 50 mg chlorthalidone (Step 1), 100 mg chlorthalidone (Step 2) and 100 chlorthalidone plus 0.25 mg reserpine (Step 3). Death, myocardial infarction, stroke, angina pectoris, and congestive heart failure were the "major" morbid events that were looked for; also recorded were "minor" morbid events consisting primarily of electrocardiographic arrhythmias. The development of significant hypertension was considered a treatment failure. Side effects were carefully tabulated in both active drug and placebo groups. The study revealed an average drop in diastolic pressure of almost 12 mm Hg for active drug group and less than half of that for the placebo group; once established 6 months after randomization, the new pressure levels persisted almost without change throughout the study. Although the feasibility trial was not designed to answer the primary question regarding the benefits of treatment, the events were tabulated for each group. A total of 12 placebo-treated subjects developed significant hypertension and were put on active drug. There was not a significant difference between the two groups in the incidence of "major" morbid events; a total of eight active and five placebo patients developed myocardial infarction or died suddenly. There, however, was an excess of arrhythmias among the active drug subjects (17 in the active group versus 8 in the placebo group on the basis of preliminary data). Finally, there were twice as many side effects and 20 times as many chemical abnormalities among the active as among the placebo subjects. A protocol for a full scale study of the benefits of pharmacologic therapy in mild hypertensives has been prepared and is ready for implementation as needed; it involves relatively minor modifications of the protocol tested in the feasibility trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1749-6632.1978.tb25604.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 91

Metadata

Authors
Neurath, H. M., Goldman, A. I., Lavin, M. A., Schnaper, H. W., Fitz, A. E., Frohlich, E. D., Steele, B., & Richman, H. G.
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
1978-03
Volume
304
Issue
1
Pages
267-287
ISSN
  • 0077-8923 (ISSN-L)
  • 1749-6632
OpenAlex
W1943534532
Cited by
91
References
1
FWCI
1.14
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EVALUATION OF DRUG TREATMENT IN MILD HYPERTENSION: VA‐NHLBI FEASIBILITY TRIAL*: Plan and Preliminary Results of a Two‐Year Feasibility Trial for a Multicenter Intervention Study to Evaluate the Benefits versus the Disadvantages of Treating Mild Hypertension: Prepared for the Veterans Administration‐National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension†. https://app.cochat.ai/papers/10.1111/j.1749-6632.1978.tb25604.x
The paper
Neurath, H. M., Goldman, A. I., Lavin, M. A., Schnaper, H. W., Fitz, A. E., Frohlich, E. D., Steele, B., & Richman, H. G. (1978). EVALUATION OF DRUG TREATMENT IN MILD HYPERTENSION: VA‐NHLBI FEASIBILITY TRIAL*: Plan and Preliminary Results of a Two‐Year Feasibility Trial for a Multicenter Intervention Study to Evaluate the Benefits versus the Disadvantages of Treating Mild Hypertension: Prepared for the Veterans Administration‐National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension†. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.1978.tb25604.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.